Neil P Shah

7PUBLICATIONS
28CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Biologically active moleculesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 25, 2026
Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.

|Oct 07, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Ehab Atallah, Michael S Broder, Onyee Chan

|Apr 16, 2025
How I individualize frontline treatment for chronic-phase CML.

Ariel Leyte-Vidal, Neil P Shah

|Nov 07, 2024
The promise of allosteric kinase inhibition.

Neil P Shah

|Jul 31, 2024
Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.

Ariel Leyte-Vidal, RosaAnna DeFilippis, Ian R Outhwaite

|Apr 21, 2024
BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis

Pageof 2

Frequent Collaborators

3 joint publications

Delphine Rea

2 joint publications

Ariel Monet Leyte-Vidal

1 joint publications

Diego Garrido Ruiz

1 joint publications

Inga B Leske